In a report released today, Chris Shibutani from Cowen & Co. maintained a Hold rating on Puma Biotechnology (PBYI), with a price target of $25. The company’s shares opened today at $11.13, close to its 52-week low of $8.45.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 5.7% and a 40.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Puma Biotechnology has an analyst consensus of Moderate Sell, with a price target consensus of $19.29.
See today’s analyst top recommended stocks >>
Based on Puma Biotechnology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.09 million. In comparison, last year the company had a GAAP net loss of $44.34 million.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.
